Latest News for: ttx
Edit
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
PR Newswire 05 Feb 2026
Food and Drug Administration (FDA) of an Investigational New Drug (IND) application amendment for a planned Phase 2a clinical trial with TransCode's lead therapeutic candidate, TTX-MC138.
Edit
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 (Form 8-K) (Transcode Therapeutics Inc)
Public Technologies 05 Feb 2026
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 ... Phase 2a clinical trial with TransCode's lead therapeutic candidate, TTX-MC138.
Edit
The Eagle-Tribune
06 Jan 2026
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
The Eagle-Tribune
06 Jan 2026
Edit
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma (Form 8-K) (Transcode Therapeutics Inc)
Public Technologies 06 Jan 2026
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma. · TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous injection.
Edit
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
PR Newswire 11 Dec 2025
RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's lead therapeutic candidate TTX-MC138 as part of the Quantum Leap PRE-I-SPY clinical trial platform ... About TTX-MC138.
Edit
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode’s Phase 1 trial (Form 8-K) (Transcode Therapeutics Inc)
Public Technologies 11 Dec 2025
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial ... About TTX-MC138.
- 1
